Female sex steroids and glia cells: Impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network

Neuroscience and Biobehavioral Reviews

Volumn 67, Issue , 2016, Pages 125-136

  Kipp, Markus ^a   Hochstrasser, Tanja ^a   Schmitz, Christoph ^a   Beyer, Cordian ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Astroglia; Estrogen; Immune cells; Inflammation; Invasion; Microglia; Multiple sclerosis; Neuroinflammation; Neuroprotection; Progesterone

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; NEUROPROTECTIVE AGENT; SEX HORMONE;

ASTROCYTE; CELL COMMUNICATION; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; GLIA CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL NETWORK; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; ANIMAL; FEMALE; GLIA; PREGNANCY;

ANIMALS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MULTIPLE SCLEROSIS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PREGNANCY; PROGESTERONE;

EID: 84952045025     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.11.016     Document Type: Review

References (223)

1. Acaz-Fonseca, E., et al. Sex differences in glia reactivity after cortical brain injury. Glia, 2015.
2. Acs, P., et al. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:8 (2009), 807–814.
3. Agrawal, S., et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203:4 (2006), 1007–1019.
4. Amantea, D., et al. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol. Res. 52:2 (2005), 119–132.
5. Amantea, D., et al. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 276:1 (2009), 13–26.
6. Ambrosini, E., Aloisi, F., Chemokines and glial cells: a complex network in the central nervous system. Neurochem. Res. 29:5 (2004), 1017–1038.
7. Amor, S., Woodroofe, M.N., Innate and adaptive immune responses in neurodegeneration and repair. Immunology 141:3 (2014), 287–291.
8. Annunziato, L., Boscia, F., Pignataro, G., Ionic transporter activity in astrocytes, microglia, and oligodendrocytes during brain ischemia. J. Cereb. Blood Flow Metab. 33:7 (2013), 969–982.
9. Arevalo, M.A., et al. Actions of estrogens on glial cells: Implications for neuroprotection. Biochim. Biophys. Acta 1800:10 (2010), 1106–1112.
10. Babcock, A.A., et al. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23:21 (2003), 7922–7930.
11. Bajramovic, J.J., Regulation of innate immune responses in the central nervous system. CNS Neurol. Disord. Drug Targets 10:1 (2011), 4–24.
12. Baker, A.E., Brautigam, V.M., Watters, J.J., Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta. Endocrinology 145:11 (2004), 5021–5032.
13. Balabanov, R., et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27:8 (2007), 2013–2024.
14. Bali, N., et al. Progesterone antagonism of neurite outgrowth depends on microglial activation via Pgrmc1/S2R. Endocrinology 154:7 (2013), 2468–2480.
15. Barnett, M.H., Prineas, J.W., Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55:4 (2004), 458–468.
16. Barres, B.A., The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60:3 (2008), 430–440.
17. Barreto, G., et al. Astrocytes: targets for neuroprotection in stroke. Cent. Nerv. Syst. Agents Med. Chem. 11:2 (2011), 164–173.
18. Becher, B., Prat, A., Antel, J., Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29:4 (2000), 293–304.
19. Becher, B., et al. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193:8 (2001), 967–974.
20. Bechmann, I., et al. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 27:1 (1999), 62–74.
21. Bechmann, I., Galea, I., Perry, V.H., What is the blood-brain barrier (not)?. Trends Immunol. 28:1 (2007), 5–11.
22. Bedoya, S.K., et al. Th17 cells in immunity and autoimmunity. Clin. Dev. Immunol., 2013, 2013, 986789.
23. Belarbi, K., Rosi, S., Modulation of adult-born neurons in the inflamed hippocampus. Front. Cell. Neurosci., 7, 2013, 145.
24. Benedict, R.H., Zivadinov, R., Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 7:6 (2011), 332–342.
25. Blakemore, W.F., Franklin, R.J., Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318 (2008), 193–212.
26. Blakemore, W.F., Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J. Neurocytol. 1:4 (1972), 413–426.
27. Blasko, E., et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J. Neuroimmunol. 214:1–2 (2009), 67–77.
28. Bo, L., et al. Grey matter pathology in multiple sclerosis. Acta Neurol. Scand. Suppl. 183 (2006), 48–50.
29. Bondesson, M., et al. Estrogen receptor signaling during vertebrate development. Biochim. Biophys. Acta 1849:2 (2015), 142–151.
30. Brinton, R.D., et al. Progesterone receptors: form and function in brain. Front. Neuroendocrinol. 29:2 (2008), 313–339.
31. Bruce-Keller, A.J., et al. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 141:10 (2000), 3646–3656.
32. Bsibsi, M., et al. Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-gamma and alpha B-crystallin. Acta Neuropathol. 128:2 (2014), 215–229.
33. Buschmann, J.P., et al. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J. Mol. Neurosci. 48:1 (2012), 66–76.
34. Carlton, W.W., Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol. Appl. Pharmacol. 8:3 (1966), 512–521.
35. Carson, M.J., Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 40:2 (2002), 218–231.
36. Cekanaviciute, E., et al. Astrocytic transforming growth factor-beta signaling reduces subacute neuroinflammation after stroke in mice. Glia 62:8 (2014), 1227–1240.
37. Chen, Z., Trapp, B.D., Microglia and neuroprotection. J. Neurochem., 2015.
38. Chen, J., Heme oxygenase in neuroprotection: from mechanisms to therapeutic implications. Rev. Neurosci. 25:2 (2014), 269–280.
39. Chesik, D., De Keyser, J., Progesterone and dexamethasone differentially regulate the IGF-system in glial cells. Neurosci. Lett. 468:3 (2010), 178–182.
40. Clarner, T., et al. CXCL10 triggers early microglial activation in the cuprizone model. J. Immunol. 194:7 (2015), 3400–3413.
41. Coles, A.J., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46:3 (1999), 296–304.
42. Confavreux, C., et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339:5 (1998), 285–291.
43. Cook-Mills, J.M., Marchese, M.E., Abdala-Valencia, H., Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid. Redox Signal. 15:6 (2011), 1607–1638.
44. Corps, K.N., Roth, T.L., McGavern, D.B., Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 72:3 (2015), 355–362.
45. Crawford, D.K., et al. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 133:10 (2010), 2999–3016.
46. Cross, A.K., Woodroofe, M.N., Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 28:3 (1999), 183–189.
47. D'Agostino, P.M., et al. Brain dendritic cells: biology and pathology. Acta Neuropathol. 124:5 (2012), 599–614.
48. Danchenko, N., Satia, J.A., Anthony, M.S., Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:5 (2006), 308–318.
49. Dang, J., et al. Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats. Brain Behav. Immun. 25:4 (2011), 715–726.
50. Das, M., Mohapatra, S., Mohapatra, S.S., New perspectives on central and peripheral immune responses to acute traumatic brain injury. J. Neuroinflamm., 9, 2012, 236.
51. Davalos, D., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8:6 (2005), 752–758.
52. De Groot, C.J., et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 124:Pt 8 (2001), 1635–1645.
53. De Nicola, A.F., et al. Progesterone protective effects in neurodegeneration and neuroinflammation. J. Neuroendocrinol. 25:11 (2013), 1095–1103.
54. Dhandapani, K.M., et al. Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 146:6 (2005), 2749–2759.
55. Dimayuga, F.O., et al. Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. J. Neuroimmunol. 161:1–2 (2005), 123–136.
56. Drew, P.D., Chavis, J.A., Female sex steroids: effects upon microglial cell activation. J. Neuroimmunol. 111:1–2 (2000), 77–85.
57. El-Etr, M., et al. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas 68:1 (2011), 47–51.
58. El-Etr, M., et al. Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortex. Glia 63:1 (2015), 104–117.
59. Ellwardt, E., Zipp, F., Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 262:Pt A (2014), 8–17.
60. Eng, L.F., Ghirnikar, R.S., Lee, Y.L., Inflammation in EAE: role of chemokine/cytokine expression by resident and infiltrating cells. Neurochem. Res. 21:4 (1996), 511–525.
61. Fernandez-Fernandez, S., Almeida, A., Bolanos, J., Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem. J. 443:1 (2012), 3–11.
62. Ferrini, F., De Koninck, Y., Microglia control neuronal network excitability via BDNF signalling. Neural Plast., 2013, 2013, 429815.
63. Finkelsztejn, A., et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 118:7 (2011), 790–797.
64. Frankenberger, M., Haussinger, K., Ziegler-Heitbrock, L., Liposomal methylprednisolone differentially regulates the expression of TNF and IL-10 in human alveolar macrophages. Int. Immunopharmacol. 5:2 (2005), 289–299.
65. Freitas-Andrade, M., Naus, C.C., Astrocytes in neuroprotection and neurodegeneration: the role of connexin43 and pannexin1. Neuroscience, 2015.
66. Fulmer, C.G., et al. Astrocyte-derived BDNF supports myelin protein synthesis after cuprizone-induced demyelination. J. Neurosci. 34:24 (2014), 8186–8196.
67. Fumagalli, S., et al. The ischemic environment drives microglia and macrophage function. Front. Neurol., 6, 2015, 81.
68. Gago, N., et al. Progesterone and the oligodendroglial lineage: stage-dependent biosynthesis and metabolism. Glia 36:3 (2001), 295–308.
69. Galbiati, M., Saredi, S., Melcangi, R.C., Steroid hormones and growth factors act in an integrated manner at the levels of hypothalamic astrocytes: a role in the neuroendocrine control of reproduction. Ann. N. Y. Acad. Sci. 1007 (2003), 162–168.
70. Galea, E., et al. Intrinsic regulation of brain inflammatory responses. Cell. Mol. Neurobiol. 23:4–5 (2003), 625–635.
71. Garcia, J.A., et al. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J. Immunol. 191:3 (2013), 1063–1072.
72. Garcia-Segura, L.M., et al. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neuroscience 89:2 (1999), 567–578.
73. Giatti, S., et al. Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. Neurochem. Int. 56:1 (2010), 118–127.
74. Giraud, S.N., et al. Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc. Natl. Acad. Sci. U.S.A. 107:18 (2010), 8416–8421.
75. Gold, S.M., Voskuhl, R.R., Estrogen and testosterone therapies in multiple sclerosis. Prog. Brain Res. 175 (2009), 239–251.
76. Gold, R., Linington, C., Lassmann, H., Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:Pt 8 (2006), 1953–1971.
77. Goldmann, T., et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 34:12 (2015), 1612–1629.
78. Gravel, M., et al. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase: a novel RNA-binding protein that inhibits protein synthesis. J. Neurosci. Res. 87:5 (2009), 1069–1079.
79. Habib, P., Beyer, C., Regulation of brain microglia by female gonadal steroids. J. Steroid. Biochem. Mol. Biol. 146 (2015), 3–14.
80. Habib, P., et al. Sex steroid hormone-mediated functional regulation of microglia-like BV-2 cells during hypoxia. J. Steroid Biochem. Mol. Biol. 138 (2013), 195–205.
81. Habib, P., et al. Hypoxia-induced gene expression of aquaporin-4, cyclooxygenase-2 and hypoxia-inducible factor 1alpha in rat cortical astroglia is inhibited by 17beta-estradiol and progesterone. Neuroendocrinology 99:3–4 (2014), 156–167.
82. Habib, P., et al. Regulation of hypoxia-induced inflammatory responses and M1–M2 phenotype switch of primary rat microglia by sex steroids. J. Mol. Neurosci. 52:2 (2014), 277–285.
83. Haider, L., et al. Oxidative damage in multiple sclerosis lesions. Brain 134:Pt 7 (2011), 1914–1924.
84. Heiman, A., et al. Toll-like receptors in central nervous system injury and disease: a focus on the spinal cord. Brain Behav. Immun. 42 (2014), 232–245.
85. Henderson, A.P., et al. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 66:6 (2009), 739–753.
86. Heppner, F.L., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11:2 (2005), 146–152.
87. Herder, V., et al. Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system. Neuropathol. Appl. Neurobiol. 37:6 (2011), 676–684.
88. Hewett, J.A., Determinants of regional and local diversity within the astroglial lineage of the normal central nervous system. J. Neurochem. 110:6 (2009), 1717–1736.
89. Hirahara, Y., et al. G protein-coupled receptor 30 contributes to improved remyelination after cuprizone-induced demyelination. Glia 61:3 (2013), 420–431.
90. Horvat, S., Beyer, C., Arnold, S., Effect of hypoxia on the transcription pattern of subunit isoforms and the kinetics of cytochrome c oxidase in cortical astrocytes and cerebellar neurons. J. Neurochem. 99:3 (2006), 937–951.
91. Hussain, R., et al. Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology 152:10 (2011), 3820–3831.
92. Janssen, K., et al. Absence of CCL2 and CCL3 ameliorates central nervous system grey matter but not white matter demyelination in the presence of an intact blood-brain barrier. Mol. Neurobiol., 2015.
93. Jarvela, J.T., et al. Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus. J. Neuroinflammation, 8, 2011, 29.
94. Jebelli, J., et al. Glia: guardians, gluttons, or guides for the maintenance of neuronal connectivity?. Ann. N. Y. Acad. Sci., 2015.
95. Johann, S., Beyer, C., Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia. J. Steroid Biochem. Mol. Biol. 137 (2013), 71–81.
96. Karki, P., et al. Astrocyte-derived growth factors and estrogen neuroprotection: role of transforming growth factor-alpha in estrogen-induced upregulation of glutamate transporters in astrocytes. Mol. Cell. Endocrinol. 389:1–2 (2014), 58–64.
97. Karve, I.P., Taylor, J.M., Crack, P.J., The contribution of astrocytes and microglia to traumatic brain injury. Br. J. Pharmacol., 2015.
98. Kerschensteiner, M., et al. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53:3 (2003), 292–304.
99. Khalaj, A.J., et al. Estrogen receptor (ER) beta expression in oligodendrocytes is required for attenuation of clinical disease by an ERbeta ligand. Proc. Natl. Acad. Sci. U.S.A. 110:47 (2013), 19125–19130.
100. Kigerl, K.A., et al. Pattern recognition receptors and central nervous system repair. Exp. Neurol. 258 (2014), 5–16.
101. Kim, H., et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem. Biophys. Res. Commun. 372:1 (2008), 243–248.
102. Kim, R.Y., et al. Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 274:1–2 (2014), 53–61.
103. Kipp, M., et al. Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. Front. Neuroendocrinol. 27:4 (2006), 376–390.
104. Kipp, M., et al. Brain-region-specific astroglial responses in vitro after LPS exposure. J. Mol. Neurosci. 35:2 (2008), 235–243.
105. Kipp, M., et al. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 118:6 (2009), 723–736.
106. Kipp, M., van der Valk, P., Amor, S., Pathology of multiple sclerosis. CNS Neurol. Disord. Drug Targets 11:5 (2012), 506–517.
107. Kipp, M., et al. Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult. Scler. Relat. Disord. 1:1 (2012), 15–28.
108. Kipp, M., et al. Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender. Front. Neuroendocrinol. 33:1 (2012), 1–16.
109. Kipp, M., et al. Sex steroids control neuroinflammatory processes in the brain: relevance for acute ischaemia and degenerative demyelination. J. Neuroendocrinol. 24:1 (2012), 62–70.
110. Kleinewietfeld, M., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496:7446 (2013), 518–522.
111. Kohno, H., et al. CCL3 production by microglial cells modulates disease severity in murine models of retinal degeneration. J. Immunol. 192:8 (2014), 3816–3827.
112. Krauspe, B.M., et al. Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration. J. Mol. Neurosci. 55:3 (2015), 733–748.
113. Kroenke, M.A., Segal, B.M., Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 85:8 (2007), 1685–1693.
114. Kumar, S., et al. Estrogen receptor beta ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol. Dis. 56 (2013), 131–144.
115. Kuo, J., et al. Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. J. Neurosci. 30:39 (2010), 12950–12957.
116. Labombarda, F., et al. Progesterone attenuates astro- and microgliosis and enhances oligodendrocyte differentiation following spinal cord injury. Exp. Neurol. 231:1 (2011), 135–146.
117. Lacroix-Fralish, M.L., et al. Differential regulation of neuregulin 1 expression by progesterone in astrocytes and neurons. Neuron Glia Biol. 2:4 (2006), 227–234.
118. Lang, B.T., et al. Pleiotropic molecules in axon regeneration and neuroinflammation. Exp. Neurol. 258 (2014), 17–23.
119. Lassmann, H., Multiple sclerosis: lessons from molecular neuropathology. Exp. Neurol. 262:Pt A (2014), 2–7.
120. Lecca, D., et al. Purinergic trophic signalling in glial cells: functional effects and modulation of cell proliferation, differentiation, and death. Purinergic Signal. 8:3 (2012), 539–557.
121. Lee, Y., et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487:7408 (2012), 443–448.
122. Lei, B., et al. Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. PLoS ONE, 9(7), 2014, e103969.
123. Leussink, V.I., et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58:1 (2001), 91–97.
124. Levin, E.R., Extranuclear steroid receptors are essential for steroid hormone actions. Annu. Rev. Med. 66 (2015), 271–280.
125. Levine, J.B., et al. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 28:3 (1999), 215–224.
126. Liberski, P.P., Sklodowski, A., Klimek, Creutzfeldt-Jakob disease: ultrastructural study of brain biopsy: unusual interaction between astrocytes and oligo- and microglia. Folia Neuropathol. 33:2 (1995), 85–92.
127. Lim, D.G., et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl. Immunol. 18:2 (2007), 94–100.
128. Liu, X., et al. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 81:5 (2005), 653–665.
129. Liu, W., Tang, Y., Feng, J., Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci. 89:5–6 (2011), 141–146.
130. Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:4 (1996), 907–911.
131. Lucchinetti, C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:6 (2000), 707–717.
132. Lucchinetti, C.F., Bruck, W., Lassmann, H., Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol., 56(2), 2004, 308.
133. Luessi, F., Siffrin, V., Zipp, F., Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev. Neurother. 12:9 (2012), 1061–1076 quiz 1077.
134. Maggi, P., et al. The formation of inflammatory demyelinated lesions in cerebral white matter. Ann. Neurol. 76:4 (2014), 594–608.
135. Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14:2 (2015), 183–193.
136. Matyszak, M.K., et al. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur. J. Immunol. 29:10 (1999), 3063–3076.
137. McDonald, W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:1 (2001), 121–127.
138. Meffre, D., et al. The membrane-associated progesterone-binding protein 25-Dx is expressed in brain regions involved in water homeostasis and is up-regulated after traumatic brain injury. J. Neurochem. 93:5 (2005), 1314–1326.
139. Meffre, D., et al. Distribution of membrane progesterone receptor alpha in the male mouse and rat brain and its regulation after traumatic brain injury. Neuroscience 231 (2013), 111–124.
140. Mena, M.A., Garcia de Yebenes, J., Glial cells as players in Parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist 14:6 (2008), 544–560.
141. Mendel, I., Kerlero de Rosbo, N., Ben-Nun, A., A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 25:7 (1995), 1951–1959.
142. Micevych, K., Sinchak, Estradiol regulation of progesterone synthesis in the brain. Mol. Cell. Endocrinol. 290:1–2 (2008), 44–50.
143. Michailidou, I., et al. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann. Neurol. 77:6 (2015), 1007–1026.
144. Mifsud, G., et al. Oligodendrocyte pathophysiology and treatment strategies in cerebral ischemia. CNS Neurosci. Ther. 20:7 (2014), 603–612.
145. Miller, S.D., Karpus, W.J., Davidson, T.S., Experimental autoimmune encephalomyelitis in the mouse. Curr. Protoc. Immunol., 2010 Chapter 15: Unit 15.1.
146. Miyamoto, N., et al. Crosstalk between cerebral endothelium and oligodendrocyte. Cell. Mol. Life Sci. 71:6 (2014), 1055–1066.
147. Moehle, M.S., West, A.B., M1 and M2 immune activation in Parkinson's disease: foe and ally?. Neuroscience, 2014.
148. Moll, N.M., et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann. Neurol. 70:5 (2011), 764–773.
149. Nalbandian, G., Kovats, S., Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol. Res. 31:2 (2005), 91–106.
150. Nimmerjahn, A., Kirchhoff, F., Helmchen, F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:5726 (2005), 1314–1318.
151. Niranjan, R., Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation. Mol. Neurobiol. 48:3 (2013), 412–428.
152. Nurulain, S.M., et al. Sub-chronic exposure of non-observable adverse effect dose of terbufos sulfone: neuroinflammation in diabetic and non-diabetic rats. CNS Neurol. Disord. Drug Targets 13:8 (2014), 1397–1405.
153. Olah, M., et al. Microglia phenotype diversity. CNS Neurol. Disord. Drug Targets 10:1 (2011), 108–118.
154. Olah, M., et al. Identification of a microglia phenotype supportive of remyelination. Glia 60:2 (2012), 306–321.
155. Orihuela, R., McPherson, C.A., Harry, G.J., Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol., 2015.
156. Park, J., et al. Disruption of Nectin-like 1 cell adhesion molecule leads to delayed axonal myelination in the CNS. J. Neurosci. 28:48 (2008), 12815–12819.
157. Pawlak, J., et al. Estrogen receptor-alpha is associated with the plasma membrane of astrocytes and coupled to the MAP/Src-kinase pathway. Glia 50:3 (2005), 270–275.
158. Pawlak, J., et al. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res. Mol. Brain Res. 138:1 (2005), 1–7.
159. Pekny, M., Wilhelmsson, U., Pekna, M., The dual role of astrocyte activation and reactive gliosis. Neurosci. Lett. 565 (2014), 30–38.
160. Pender, M.P., et al. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J. Neurol. Sci. 104:1 (1991), 81–87.
161. Pettinelli, C.B., McFarlin, D.E., Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J. Immunol. 127:4 (1981), 1420–1423.
162. Petzold, A., et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125:Pt 7 (2002), 1462–1473.
163. Platania, P., et al. 17beta-estradiol rescues spinal motoneurons from AMPA-induced toxicity: a role for glial cells. Neurobiol. Dis. 20:2 (2005), 461–470.
164. Ramesh, G., MacLean, A.G., Philipp, M.T., Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm., 2013, 2013, 480739.
165. Ransohoff, R.M., Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 15:8 (2012), 1074–1077.
166. Rao, K.V., et al. Astrocytes protect neurons from ammonia toxicity. Neurochem. Res. 30:10 (2005), 1311–1318.
167. Rasband, M.N., et al. CNP is required for maintenance of axon-glia interactions at nodes of Ranvier in the CNS. Glia 50:1 (2005), 86–90.
168. Rasmussen, S., et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing—remitting experimental autoimmune encephalomyelitis. Brain 130:Pt 11 (2007), 2816–2829.
169. Reed, J.L., et al. Estrogen increases proteasome activity in murine microglial cells. Neurosci. Lett. 367:1 (2004), 60–65.
170. Rice, G.P., Filippi, M., Comi, G., Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 54:5 (2000), 1145–1155.
171. Rinholm, J.E., et al. Regulation of oligodendrocyte development and myelination by glucose and lactate. J. Neurosci. 31:2 (2011), 538–548.
172. Rossi, D., Astrocyte physiopathology: at the crossroads of intercellular networking, inflammation and cell death. Prog. Neurobiol., 2015.
173. Rozkova, D., et al. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120:3 (2006), 260–271.
174. Saijo, K., et al. An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 145:4 (2011), 584–595.
175. Saldanha, C.J., Duncan, K.A., Walters, B.J., Neuroprotective actions of brain aromatase. Front. Neuroendocrinol. 30:2 (2009), 106–118.
176. Salmina, A.B., Neuron-glia interactions as therapeutic targets in neurodegeneration. J. Alzheimers Dis. 16:3 (2009), 485–502.
177. Sarvari, M., et al. Ovariectomy and subsequent treatment with estrogen receptor agonists tune the innate immune system of the hippocampus in middle-aged female rats. PLoS ONE, 9(2), 2014, e88540.
178. Selvamani, A., et al. An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS ONE, 7(2), 2012, e32662.
179. Shivers, R.R., Arthur, F.E., Bowman, P.D., Induction of gap junctions and brain endothelium-like tight junctions in cultured bovine endothelial cells: local control of cell specialization. J. Submicrosc. Cytol. Pathol. 20:1 (1988), 1–14.
180. Sierra, A., et al. Steroid hormone receptor expression and function in microglia. Glia 56:6 (2008), 659–674.
181. Silver, J., Miller, J.H., Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5:2 (2004), 146–156.
182. Singhal, G., et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci., 8, 2014, 315.
183. Skalnikova, H., et al. Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines. Proteomics 11:4 (2011), 691–708.
184. Skaper, S.D., The brain as a target for inflammatory processes and neuroprotective strategies. Ann. N. Y. Acad. Sci. 1122 (2007), 23–34.
185. Skripuletz, T., et al. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 26:12 (2011), 1585–1597.
186. Skuljec, J., et al. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell. Immunol. 270:2 (2011), 164–171.
187. Slowik, A., Beyer, C., Inflammasomes are neuroprotective targets for sex steroids. J. Steroid Biochem. Mol. Biol., 2015.
188. Sofroniew, M.V., Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16:5 (2015), 249–263.
189. Sohrabji, F., Estrogen-IGF-1 interactions in neuroprotection: ischemic stroke as a case study. Front. Neuroendocrinol. 36 (2015), 1–14.
190. Soos, J.M., et al. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int. Immunol. 11:7 (1999), 1169–1179.
191. Sosa, R.A., et al. The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 191:12 (2013), 5848–5857.
192. Spence, R.D., Voskuhl, R.R., Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front. Neuroendocrinol. 33:1 (2012), 105–115.
193. Spence, R.D., et al. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERalpha signaling on astrocytes but not through ERbeta signaling on astrocytes or neurons. J. Neurosci. 33:26 (2013), 10924–10933.
194. Starossom, S.C., et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37:2 (2012), 249–263.
195. Stein, M., et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176:1 (1992), 287–292.
196. Stidworthy, M.F., et al. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol. 13:3 (2003), 329–339.
197. Stoll, G., Jander, S., Schroeter, M., Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 56:2 (1998), 149–171.
198. Stys, P.K., et al. Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 13:7 (2012), 507–514.
199. Sun, P., et al. Activating transcription factor 4 modulates BDNF release from microglial cells. J. Mol. Neurosci. 52:2 (2014), 225–230.
200. Takano, T., et al. Astrocytes and ischemic injury. Stroke 40:3 Suppl (2009), S8–S12.
201. Tan, I.J., Peeva, E., Zandman-Goddard, G., Hormonal modulation of the immune system—a spotlight on the role of progestogens. Autoimmun. Rev. 14:6 (2015), 536–542.
202. Tao-Cheng, J.H., Nagy, Z., Brightman, M.W., Tight junctions of brain endothelium in vitro are enhanced by astroglia. J. Neurosci. 7:10 (1987), 3293–3299.
203. Theien, B.E., et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102:13 (2003), 4464–4471.
204. Trager, U., Tabrizi, S.J., Peripheral inflammation in neurodegeneration. J. Mol. Med. (Berl.) 91:6 (2013), 673–681.
205. Ulvestad, E., et al. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J. Leukoc. Biol. 56:6 (1994), 732–740.
206. van der Star, B.J., et al. In vitro and in vivo models of multiple sclerosis. CNS Neurol. Disord. Drug Targets 11:5 (2012), 570–588.
207. Vegeto, E., et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. U.S.A. 100:16 (2003), 9614–9619.
208. Vegeto, E., et al. The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 147:5 (2006), 2263–2272.
209. Velasco, I., Stem cells with neurogenic potential and steroid hormones. Curr. Top. Med. Chem. 11:13 (2011), 1684–1693.
210. Vella, J., et al. The central role of aquaporins in the pathophysiology of ischemic stroke. Front. Cell. Neurosci., 9, 2015, 108.
211. Verkhratsky, A., Parpura, V., Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. Neurobiol. Dis., 2015.
212. Voskuhl, R.R., et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J. Neurosci. 29:37 (2009), 11511–11522.
213. Whitacre, C.C., Sex differences in autoimmune disease. Nat. Immunol. 2:9 (2001), 777–780.
214. Woodcock, T., Morganti-Kossmann, M.C., The role of markers of inflammation in traumatic brain injury. Front. Neurol., 4, 2013, 18.
215. Wu, W.F., et al. Targeting estrogen receptor beta in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 110:9 (2013), 3543–3548.
216. Xiao, L., et al. Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination. Glia 60:7 (2012), 1037–1052.
217. Ye, J.N., et al. Progesterone alleviates neural behavioral deficits and demyelination with reduced degeneration of oligodendroglial cells in cuprizone-induced mice. PLoS ONE, 8(1), 2013, e54590.
218. Yednock, T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:6364 (1992), 63–66.
219. Yu, Z., et al. MSX3 switches microglia polarization and protects from inflammation-induced demyelination. J. Neurosci. 35:16 (2015), 6350–6365.
220. Zendedel, A., Beyer, C., Kipp, M., Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J. Mol. Neurosci. 51:2 (2013), 567–572.
221. Zendedel, A., Habib, P., Dang, J., Lammerding, L., Hoffmann, S., Beyer, C., Slowik, A., Omega-3 polyunsaturated fatty acids ameliorate neuroinflammation and mitigate ischemic stroke damage through interactions with astrocytes and microglia. J. Neuroimmunol. 278 (2015), 200–211.
222. Zhao, Y., Rempe, D.A., Targeting astrocytes for stroke therapy. Neurotherapeutics 7:4 (2010), 439–451.
223. Zindler, E., Zipp, F., Neuronal injury in chronic CNS inflammation. Best Pract. Res. Clin. Anaesthesiol. 24:4 (2010), 551–562.